Active ingredient description

Ajmaline is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. It produces potent sodium channel blocking effects and a very short half-life which makes it a very useful drug for acute intravenous treatments. The drug has been very popular in some countries for the treatment of atrial fibrillation in patients with the Wolff–Parkinson–White syndrome and in well tolerated monomorphic ventricular tachycardias. It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope. In these cases, abnormal prolongation of the HV interval has been taken as a proof for infrahisian conduction defects tributary for permanent pacemaker implantation.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
C Cardiovascular system → C01 Cardiac therapy → C01B Antiarrhythmics, class I and III → C01BA Antiarrhythmics, class Ia
Discover more medicines within C01BA05


Ajmaline is the active ingredient of these drugs:



Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₂₀H₂₆N₂O₂
Molecular mass: 326.433 g/mol

External identifiers

CAS Substance: 4360-12-7
DrugBank Drug: DB01426
KEGG Drug: D00199
PubChem Compound: 6100671
RxNorm Ingredient: 423
UNII Identifier: 1PON08459R